癫痫（全身性发作）。
Epilepsy (generalised seizures).
作者信息
Cross J Helen
机构信息
UCL-Institute of Child Health, Great Ormond Street Hospital for Children & National Centre for Young People with Epilepsy, London, UK.
出版信息
BMJ Clin Evid. 2015 Apr 17;2015:1201.
INTRODUCTION
About 3% of people will be diagnosed with epilepsy during their lifetime, but about 70% of people with epilepsy eventually go into remission.
METHODS AND OUTCOMES
We conducted a systematic review and aimed to answer the following clinical question: What are the effects of additional treatments in people with drug-resistant epilepsy characterised by generalised seizures? We searched: Medline, Embase, The Cochrane Library, and other important databases up to April 2014 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS
We found four studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS
In this systematic review we present information relating to the effectiveness and safety on the addition of the following interventions: lacosamide, lamotrigine, levetiracetam, perampanel, and zonisamide versus the addition of placebo.
引言
约3%的人在其一生中会被诊断为癫痫，但约70%的癫痫患者最终会进入缓解期。
方法与结果
我们进行了一项系统评价，旨在回答以下临床问题：对于以全身性发作为特征的耐药性癫痫患者，附加治疗的效果如何？我们检索了：截至2014年4月的Medline、Embase、Cochrane图书馆及其他重要数据库（临床证据综述会定期更新；请查看我们的网站获取本综述的最新版本）。我们纳入了来自美国食品药品监督管理局（FDA）和英国药品和医疗产品监管局（MHRA）等相关组织的危害警示。
结果
我们发现四项符合纳入标准的研究。我们对干预措施的证据质量进行了GRADE评估。
结论
在本系统评价中，我们呈现了以下干预措施附加治疗的有效性和安全性相关信息：拉科酰胺、拉莫三嗪、左乙拉西坦、吡仑帕奈和唑尼沙胺与附加安慰剂相比。
Zotero 插件